Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1972 Jul;51(7):1813–1822. doi: 10.1172/JCI106983

Studies on the Interaction between Collagen and a Plasma Kallikrein-Like Activity EVIDENCE FOR A SURFACE-ACTIVE ENZYME SYSTEM

Peter C Harpel 1
PMCID: PMC292329  PMID: 4338122

Abstract

This study has demonstrated that collagen particles, after exposure to platelet-poor human plasma and subsequent washing, generate a kinin-like agent when incubated with prekinin substrate. The binding of kinin-generating activity to collagen in the plasma collagen incubation mixture occurs rapidly, whereas the loss of this activity in the incubation mixture occurs relatively slowly. The Hageman factor appeared to be necessary for the surface-bound kinin-generating activity, as this activity was absent in collagen exposed to Hageman factor-deficient plasma. These studies have partially characterized the plasma-derived enzymatic activity bound to collagen. Incubation of collagen with plasma caused a concentration-dependent reduction in the kinin-producing activity which was generated by the addition of ellagic acid, a known activator of plasma kallikrein. The kinin-inducing activity bound to collagen is inhibited by soybean trypsin inhibitor, Trasylol, serum C1̄ inactivator and the plasma α2-macroglobulin, but not by lima bean trypsin inhibitor. An eluate prepared from plasma-treated collagen, when compared with purified plasma kallikrein, shared a similar inhibitor profile. Selective chemical blockage of the free carboxyl groups on the collagen molecule, or heat denaturation, inactivated the ability of the collagen to generate kinin-like activity after incubation with plasma. Removal of the collagen telopeptides or blockage of the free amino groups failed to affect the collagen-plasma interaction. The binding of partially purified plasma kallikrein to collagen was found to have similar structural and chemical requirements. These data indicate that there is a structural and chemical specificity for the activation and binding of plasma kallikrein-like activity by collagen. These studies suggest that a plasma kallikrein may function as a surface-bound enzyme system.

Full text

PDF
1813

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BECKER E. L., KAGEN L. THE PERMEABILITY GLOBULINS OF HUMAN SERUM AND THE BIOCHEMICAL MECHANISM OF HEREDITARY ANGIONEUROTIC EDEMA. Ann N Y Acad Sci. 1964 Aug 27;116:866–873. doi: 10.1111/j.1749-6632.1964.tb52552.x. [DOI] [PubMed] [Google Scholar]
  2. BOTTI R. E., RATNOFF O. D. STUDIES ON THE PATHOGENESIS OF THROMBOSIS: AN EXPERIMENTAL "HYPERCOAGULABLE" STATE INDUCED BY THE INTRAVENOUS INJECTION OF ELLAGIC ACID. J Lab Clin Med. 1964 Sep;64:385–398. [PubMed] [Google Scholar]
  3. BOWES J. H., MOSS J. A. The reaction of fluorodinitrobenzene with the alpha- and beta-amino groups of collagen. Biochem J. 1953 Dec;55(5):735–741. doi: 10.1042/bj0550735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Back N., Steger R. Effect of inhibitors on kinin-releasing activity of proteases. Fed Proc. 1968 Jan-Feb;27(1):96–99. [PubMed] [Google Scholar]
  5. DAVIES G. E., LOWE J. S. A permeability factor released from guinea-pig serum by antigen-antibody precipitates. Br J Exp Pathol. 1960 Aug;41:335–344. [PMC free article] [PubMed] [Google Scholar]
  6. ELDER J. M., WILHELM D. L. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. V. Activable permeability factor in human serum. Br J Exp Pathol. 1958 Aug;39(4):335–342. [PMC free article] [PubMed] [Google Scholar]
  7. ERDOS E. G., SLOANE E. M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol. 1962 Jul;11:585–592. doi: 10.1016/0006-2952(62)90119-3. [DOI] [PubMed] [Google Scholar]
  8. Eisen V., Smith H. G. Plasma kinin formation by complexes of aggregated gamma-globulin and serum proteins. Br J Exp Pathol. 1970 Jun;51(3):328–331. [PMC free article] [PubMed] [Google Scholar]
  9. FASCIOLO J. C. BRADYKININOGEN, ANGIOTENSINOGEN AND KALLIDINOGEN. Br J Pharmacol Chemother. 1963 Oct;21:250–258. doi: 10.1111/j.1476-5381.1963.tb01524.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med. 1970 Nov;76(5):809–815. [PubMed] [Google Scholar]
  11. Ganrot P. O. Inhibition of plasmin activity by alpha-2-macroglobulin. Clin Chim Acta. 1967 May;16(2):328–329. doi: 10.1016/0009-8981(67)90201-x. [DOI] [PubMed] [Google Scholar]
  12. Gautvik K. M., Rugstad H. E. Kinin formation and kininogen depletion in rats after intravenous injection of ellagic acid. Br J Pharmacol Chemother. 1967 Nov;31(3):390–400. doi: 10.1111/j.1476-5381.1967.tb00406.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gigli I., Mason J. W., Colman R. W., Austen K. F. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol. 1970 Mar;104(3):574–581. [PubMed] [Google Scholar]
  14. Harpel P. C. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med. 1970 Aug 1;132(2):329–352. doi: 10.1084/jem.132.2.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Harpel P. C. Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor. J Clin Invest. 1971 Oct;50(10):2084–2090. doi: 10.1172/JCI106702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kellermeyer R. W., Graham R. C., Jr Kinins--possible physiologic and pathologic roles in man. N Engl J Med. 1968 Oct 3;279(14):754–759. doi: 10.1056/NEJM196810032791406. [DOI] [PubMed] [Google Scholar]
  17. Lanchantin G. F., Plesset M. L., Friedmann J. A., Hart D. W. Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macroglobulin. Proc Soc Exp Biol Med. 1966 Feb;121(2):444–449. doi: 10.3181/00379727-121-30800. [DOI] [PubMed] [Google Scholar]
  18. MARGOLIS J. Activation of a permeability factor in plasma by contact with glass. Nature. 1958 Mar 1;181(4609):635–636. doi: 10.1038/181635a0. [DOI] [PubMed] [Google Scholar]
  19. MARGOLIS J. The mode of action of Hageman factor in the release of plasma kinin. J Physiol. 1960 May;151:238–252. doi: 10.1113/jphysiol.1960.sp006434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Marcus A. J. Platelet function (third of three parts). N Engl J Med. 1969 Jun 12;280(24):1330–1335. doi: 10.1056/NEJM196906122802405. [DOI] [PubMed] [Google Scholar]
  21. Nemerson Y. The phospholipid requirement of tissue factor in blood coagulation. J Clin Invest. 1968 Jan;47(1):72–80. doi: 10.1172/JCI105716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Niewiarowski S., Bańkowski E., Fiedoruk T. Adsorption of Hageman factor (Factor XII) on collagen. Experientia. 1964 Jul 15;20(7):367–368. doi: 10.1007/BF02147961. [DOI] [PubMed] [Google Scholar]
  23. Niewiarowski S., Bańkowski E., Rogowicka I. Studies on the adsorption and activation of the Hageman factor (factor XII) by collagen and elastin. Thromb Diath Haemorrh. 1965 Nov 15;14(3-4):387–400. [PubMed] [Google Scholar]
  24. Pettinger W. A., Young R. Endotoxin-induced kinin (bradykinin) formation: activation of Hageman factor and plasma kallikrein in human plasma. Life Sci. 1970 Mar 15;9(6):313–322. doi: 10.1016/0024-3205(70)90219-5. [DOI] [PubMed] [Google Scholar]
  25. RATNOFF O. D., CRUM J. D. ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID. J Lab Clin Med. 1964 Mar;63:359–377. [PubMed] [Google Scholar]
  26. RATNOFF O. D., MILES A. A. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR. Br J Exp Pathol. 1964 Jun;45:328–345. [PMC free article] [PubMed] [Google Scholar]
  27. Ratnoff O. D., Pensky J., Ogston D., Naff G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med. 1969 Feb 1;129(2):315–331. doi: 10.1084/jem.129.2.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ratnoff O. D. The biology and pathology of the initial stages of blood coagulation. Prog Hematol. 1966;5:204–245. [PubMed] [Google Scholar]
  29. SPAET T. H., CINTRON J., SPIVACK M. Some properties of the platelet-connective tissue mixed agglutination reaction. Proc Soc Exp Biol Med. 1962 Nov;111:292–295. doi: 10.3181/00379727-111-27771. [DOI] [PubMed] [Google Scholar]
  30. STEVEN F. S. THE NISHIHARA TECHNIQUE FOR THE SOLUBILIZATION OF COLLAGEN. APPLICATION TO THE PREPARATION OF SOLUBLE COLLAGENS FROM NORMAL AND RHEUMATOID CONNECTIVE TISSUE. Ann Rheum Dis. 1964 Jul;23:300–301. doi: 10.1136/ard.23.4.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schachter M. Kallikreins and kinins. Physiol Rev. 1969 Jul;49(3):509–547. doi: 10.1152/physrev.1969.49.3.509. [DOI] [PubMed] [Google Scholar]
  32. WEBSTER M. E., ATNOFF O. D. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature. 1961 Oct 14;192:180–181. doi: 10.1038/192180a0. [DOI] [PubMed] [Google Scholar]
  33. WEBSTER M. E., PIERCE J. V. Action of the kallikreins on synthetic ester substrates. Proc Soc Exp Biol Med. 1961 May;107:186–191. doi: 10.3181/00379727-107-26575. [DOI] [PubMed] [Google Scholar]
  34. Wilner G. D., Nossel H. L., LeRoy E. C. Activation of Hageman factor by collagen. J Clin Invest. 1968 Dec;47(12):2608–2615. doi: 10.1172/JCI105943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wilner G. D., Nossel H. L., LeRoy E. C. Aggregation of platelets by collagen. J Clin Invest. 1968 Dec;47(12):2616–2621. doi: 10.1172/JCI105944. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES